The European Amyotrophic Lateral Sclerosis Health Profile Study

Journal of the Neurological Sciences

Volumn 160, Issue SUPPL. 1, 1998, Pages

  Jenkinson, Crispin ^a   Swash, Michael ^b   Fitzpatrick, Ray ^c  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b St Bartholamews Roy London H ^*  (United Kingdom)

^c NUFFIELD COLLEGE   (United Kingdom)

Author keywords

ALS Health Profile Study; Amyotrophic lateral sclerosis; Quality of life

Indexed keywords

AMYOTROPHIC LATERAL SCLEROSIS; CONFERENCE PAPER; EUROPE; HEALTH STATUS; HUMAN; PRIORITY JOURNAL; QUALITY OF LIFE; TREATMENT OUTCOME;

AMYOTROPHIC LATERAL SCLEROSIS; CAREGIVERS; EUROPE; HEALTH STATUS INDICATORS; HUMANS; LONGITUDINAL STUDIES; PSYCHOLOGICAL TESTS; QUALITY OF LIFE;

EID: 0031724462     PISSN: 0022510X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-510X(98)00210-X     Document Type: Conference Paper

References (31)

1. ALS CNTF Treatment Study (ACTS) Phase I-II Study Group. The amyotrophic lateral sclerosis functional rating scale. Assessment of activities of daily living in patients with amyotrophic lateral sclerosis. Arch Neurol 1996; 53:141-47.
2. Bensimon G, Lacomblez L, Meninger V, and the ALS/Riluzole Study Group. A controlled trial of riluzole in amyotrophic lateral sclerosis. New Engl J Med 1994;330:585-91.
3. Bernat JL, Vincent FM. Neurology. Oradell, NJ: Medical Economics Books, 1987.
4. Brazier JE, Harper R, Jones NMB, et al. Validating the SF-36 health survey questionnaire: New outcome measure for primary care. Br Med J 1992;305:160-4.
5. Bullinger M. German translation and psychometric testing of the SF-36 health survey: Preliminary results from the IQOLA project. Soc Sci Med 1995;41:1359-66.
6. Donaghy M. The motor neurone diseases. In: Weatherall DJ, Ledingham JGG, Warrell DA, editors. Oxford textbook of medicine, 3rd ed, vol 3. Oxford: Oxford University Press, 1996.
7. Dupuy HJ. The psychological general well-being index. In: Wenger NK, Mattson ME, Furberg CP, Elinson J, editors. Assessment of quality of life in clinical trials for cardiovascular therapies. New York: LeJacq, 1984.
8. Jenkinson C, Coulter A, Wright L. Short form 36 (SF 36) health survey questionnaire: Normative data for adults of working age. Br Med J 1993;306:1437-40.
9. Jenkinson C, Fitzpatrick R, Peto V, Greenhall R, Hyman N. Self reported functioning and well-being in patients with Parkinson's disease: comparison of the SF-36 and PDQ-39. Age Ageing 1995;24:505-9.
10. Jenkinson C, Layte R, Coulter A, Wright L. Evidence for the sensitivity of the SF-36 health status measure to inequalities in health: Results from the Oxford healthy lifestyle survey. J Epidemiol Commun Health 1996;50:377-80.
11. Jenkinson C, Layte R, Wright L, Coulter A. The UK SF-36: An analysis and interpretation manual. Oxford: Health Services Research Unit, University of Oxford, 1996.
12. Lacomblez L, Bensimon G, Leigh PN, Guillet P, Meininger V. For the Amyotrophic Lateral Sclerosis/Riluzole Study Group II. Dose-ranging study of riluzole in amyotrophic lateral sclerosis. Lancet 1996;347:1425-31.
13. Leigh PN, Swash M. Motor neurone disease. London: Springer-Verlag, 1995.
14. McDowell I, Newell C. Measuring health: A guide to rating scales and questionnaires. New York: Oxford University Press, 1987.
15. McDowell I, Newell C. Measuring health: A guide to rating scales and questionnaires, 2nd ed. New York: Oxford University Press, 1996.
16. McHorney CA, Ware JE, Lu JFR. The MOS 36-item short-form health survey (SF-36): III. Tests of data quality, scaling assumptions and reliability across diverse patient groups. Med Care 1994;32:40-66.
17. McHorney CA, Ware JE, Raczek AE. The MOS 36-item short-form health survey (SF-36): II. Psychometric and clinical tests of validity in measuring physical and mental health constructs. Med Care 1993;31:247-63.
18. Oliver DJ. Motor neurone disease: A family affair. London: Sheldon Press, 1995.
19. Robinson BC. Validation of a caregiver strain index. J Gerontol 1983;38:351-3.
20. Solomon GD, Skobieranda FG, Genzen JR. Quality of life assessment among migraine patients treated with sumatriptan. Headache 1995;35:449-54.
21. Sullivan M, Karlsson J, Ware JE. The Swedish SF-36 health survey - I. Evaluation of data quality, scaling assumptions, reliability and construct validity across general populations in Sweden. Soc Sci Med 1995;41:1349-58.
22. Tandan R, Bradley WG. Amyotrophic lateral sclerosis: part 1. Clinical features, pathology and ethical issues in management. Ann Neurol 1985;18:271-80.
23. Vickrey BG, Hays RD, Harooni R, Myers LW, Ellison GW A health related quality of life measure for multiple sclerosis. Quality Life Res 1995;4:187-206.
24. Wagner AK, Cynn DJ, Ehrenberg BL, Tran TA, Bungay KM, Rogers WH. The impact of routine health status measurement on aspects of epilepsy patient's care. Epilepsia 1995;36(Supplement 4):96.
25. Wagner AK, Keller SD, Kosinski M, et al. Advances in methods for assessing the impact of epilepsy and antiepileptic drug therapy on patients' quality of life. Quality Life Res 1995;4:115-34.
26. Ware J, Sherbourne C. The MOS 36-item short-form health survey 1: Conceptual framework and item selection. Med Care 1992;30:473-83.
27. Ware JE, Snow KK, Kosinski M, Gandek B. SF-36 health survey: Manual and interpretation guide. Boston, MA: The Health Institute, New England Medical Center, 1993.
28. Wright L. The long and the short of it: the development of the SF-36 general health survey. In: Jenkinson C, editor. Measuring health and medical outcomes. London: UCL Press, 1994.
29. World Health Organisation. The first ten years of the World Health Organisation. Geneva: WHO, 1958.
30. Bowling A. Measuring health: A review of quality of life measurement scales. 2nd ed. Buckingham: Open University Press, 1997.
31. Coulter A. Measuring quality of life. In: Kinmonth AL, Jones R, editors. Critical reading in general practice. Oxford: Oxford Univesity Press, 1993.